治疗原发性硬化性胆管炎的药物研究进展

Research progress of drugs in treating primary sclerosing cholangitis

原发性硬化性胆管炎(PSC)是一种以慢性进行性胆管炎症为特征的胆汁淤积性肝病,其发病率低,预后差,肝移植是现阶段唯一有效的治疗手段,迫切需要寻找有效的治疗药物以改善患者预后。近年开展了熊去氧胆酸、24-非熊去氧胆酸类胆汁酸、法尼醇X受体激动剂、顶端钠依赖性胆盐转运体抑制剂、过氧化物酶体增殖物激活受体激动剂及抗生素等药物在治疗PSC的临床研究,以期为寻找有效的治疗药物提供线索,改善PSC预后。

Primary sclerosing cholangitis(PSC) is a cholestatic liver disease characterized by chronic progressive inflammation of bile ducts. It has low incidence and poor prognosis, liver transplantation is the only effective treatment at this stage. It is urgent to find effective therapeutic drugs to improve the prognosis of these patients. In recent years, clinical studies have been carried out on ursodeoxycholic acid, 24-norursodeoxycholic acid, farnesoid X receptor agonists, apical sodium dependent bile salt transporter inhibitors, peroxisome proliferation-activated receptor agonists and antibiotics in the treatment of PSC, and provide clues for finding effective treatment drugs and improving the prognosis of PSC.